Tuesday, July 1, 2025

Latest

MindMed Activist Investor Moves To Take Control Of Board

MindMed (NASDAQ: MNMD) has seen its activist investor file a preliminary proxy statement for its proposed set of directors after the firm indicated last year it intended to work to take control of the company. The activist investor, FCM MM Holdings, is ran by a former co-founder of MindMed, Dr Scott Freeman.

Describing itself as “one of MindMed’s largest investors,” the firm has just a 3.5% stake in the company, yet is attempting to exert control. FCM proposed a total of four directors for the firms board, including Dr Scott Freeman, co-founder of MindMed and former Chief Medical Officer, Dr Farzin Farzaneh, a professor of molecular medicine at King’s College London, Vivek Jain, a venture capitalist, and Alexander Wodka, a former partner at Crowe.

In announcing that the filing has been made, FCM highlighted that MindMed has seen its shares decline 89% over the past year, despite its peer group falling on average 62%.

The firm also addressed recent comments by MindMed wherein the company referred to FCM as not having paid a “control premium,” which FCM claims is “simply mendacious,” given the fact that they are not seeking a buy out (they just want control instead). FCM claims that they are simply looking to repair operational challenges and restore shareholder value.

“Since 2021, I have been proactively engaging the Board about the delays in the MM-110 and MM-120 programs. Unfortunately, these entreaties were ignored, and subsequently, management botched the MM-110 program while the MM-120 program is over a year behind schedule due to a myriad of operational failures. As a result, I believe the only path forward for MindMed is an immediate reconstitution of the Board,” commented Freeman.

MindMed last traded at $3.81 on the Nasdaq.


Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Baselode Energy To Acquire Forum Energy: The Merger Of Equals Deal

TriStar Gold: The Revised Castelo de Sonhos Prefeasibility Study

Gold is Up 30%, But the Real Bull Market is Only Starting Now! | Adrian Day

Recommended

ESGold To Expand Mine Building At Montauban In Advance Of Gold & Silver Production

Goliath Resources Expands 2025 Drill Program To 60,000 Metres

Related News

Mindmed: Eight Capital Resumes Coverage With $6.50 Price Target

Earlier this week, Eight Capital launched coverage on a basket of psychedelic companies. This comes...

Friday, September 17, 2021, 03:23:00 PM

Mind Medicine Boasts Current Cash Position Of US$161 Million

Mind Medicine (NEO: MMED) this morning released its fiscal year 2020 financial results. Given that...

Tuesday, March 30, 2021, 08:19:57 AM

Champignon Brands Vs Mind Medicine: A Comparison

Champignon Brands (CSE: SHRM), prior to the public listing of the company, had a primary...

Monday, April 20, 2020, 09:01:13 AM

Canaccord Reiterates $1.75 Price Target For Mind Medicine Following Roadshow Event

This morning, Canaccord released a flash update for Mind Medicine (NEO: MMED) with highlights from...

Monday, September 28, 2020, 11:02:24 AM

MindMed Declares US$17.0 Million Net Loss, US$105.7 Million Cash Balance For Q2 2022

Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced on Thursday its financial...

Friday, August 12, 2022, 08:20:03 AM